US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Takeda Pharmaceutical Co Ltd

14.74

+0.02000.14%

Post-market: 14.740.00000.00%19:07 EDT

Volume:3.11M

Turnover:45.77M

Market Cap:46.55B

PE:65.66

High:14.79

Open:14.73

Low:14.68

Close:14.72

Loading ...

Overview Company News Filings

Will ADMA Biologics Stock Continue Its Momentum in 2025?

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda announces EMA approval for Takhzyro two mL pre-filled pen option

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

MT Newswires Live

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

ADMA Loses 8.9% in a Month: How Should You Play the Stock?

Takeda Pharmaceutical Names Julie Kim Chief Executive

MT Newswires Live

Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed

Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises

MT Newswires Live

Takeda FY2024 Guidance Raised: Core Revenue And Profit Now Expected To Grow Low Single Digits; Core EPS Revised To Flat/Slight Decline. Free Cash Flow Raised To ¥550B–¥650B.

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Pharmaceutical Q3 2024 GAAP EPS ¥15.01 Down From ¥67.38 YoY, Sales ¥1.144T Beat ¥1.139T Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TAK/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TAK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAK\",,,,,undefined,":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"Takeda Pharmaceutical Co Ltd","latestPrice":14.74,"timestamp":1752782400000,"preClose":14.72,"halted":0,"volume":3107205,"hourTrading":{"tag":"盘后","latestPrice":14.74,"preClose":14.74,"latestTime":"19:07 EDT","volume":7217,"amount":106378.65,"timestamp":1752793638394},"delay":0,"floatShares":3156280755,"shares":3158218006,"eps":0.224477,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"07-17 16:00:00 EDT","open":14.73,"high":14.79,"low":14.68,"amount":45768045.235455,"amplitude":0.007473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.224477,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752825600000},"marketStatusCode":0,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":14.72,"dividendRate":0.045995,"preHourTrading":{"tag":"盘前","latestPrice":14.72,"preClose":14.72,"latestTime":"08:00 EDT","volume":247,"amount":3588.3893239999998,"timestamp":1752753609371},"postHourTrading":{"tag":"盘后","latestPrice":14.74,"preClose":14.74,"latestTime":"19:07 EDT","volume":7217,"amount":106378.65,"timestamp":1752793638394},"volumeRatio":0.855219,"impliedVol":0.1807,"impliedVolPercentile":0.084},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAK\",,,,,undefined,":{"symbol":"TAK","floatShares":3156280755,"roa":"2.40%","roe":"1.52%","lyrEps":0.228242,"volumeRatio":0.855219,"shares":3158218006,"dividePrice":0.658658,"high":14.79,"amplitude":0.007473,"preClose":14.72,"low":14.68,"week52Low":12.8,"pbRate":"1.00","psRate":"1.51","week52High":15.53,"institutionHeld":0.09,"latestPrice":14.74,"eps":0.224477,"divideRate":0.044685,"volume":3107205,"delay":0,"ttmEps":0.224477,"open":14.73,"prevYearClose":13.24,"prevWeekClose":14.68,"prevMonthClose":15.46,"prevQuarterClose":15.46,"fiveDayClose":14.84,"twentyDayClose":14.89,"sixtyDayClose":14.93,"earningDate":1753804800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TAK\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519386307","title":"Will ADMA Biologics Stock Continue Its Momentum in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386307","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386307?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:40","pubTimestamp":1741959600,"startTime":"0","endTime":"0","summary":"ADMA Biologics ADMA put up a phenomenal performance in 2024 and the rally continues in 2025 as well.Last week, ADMA Biologics announced results for its fourth quarter and full-year 2024 and provided a business update. While adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate by a penny, revenues of $118 million beat the consensus estimate of $112 million.Nonetheless, a single quarter’s results are not important for long-term investors. Let's analyze ADMA’s fundamentals in this scenario.The company’s top line currently comprises sales of three FDA-approved products, which are Bivigam , Asceniv  and Nabi-HB .Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.Concurrent with its fourth-quarter results, ADMA upped its financial targets. ADMA now expects to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-stock-continue-momentum-134000162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ADMA","BK4139","TAK","GRFS"],"gpt_icon":0},{"id":"2516772656","title":"Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516772656","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516772656?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:01","pubTimestamp":1741021301,"startTime":"0","endTime":"0","summary":"On Monday, Protagonist Therapeutics, Inc.  and Takeda Pharmaceutical Co Ltd  released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.Polycythemia vera isa type of blood cancer. It causes your bone marrow to make too many red blood cells.Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and Fast Track designations.The study’s primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy eligibility.The first key secondary endpoint, which is the pre-specified primary endpoint for European Union  regulators, was also met, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 phlebotomies per patient in the placebo arm during weeks 0-32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-protagonist-therapeutics-partnered-investigational-170141358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","PTGX","BK4007","BK4139","BK4156","TAK"],"gpt_icon":0},{"id":"2516653268","title":"Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653268","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653268?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:40","pubTimestamp":1741012819,"startTime":"0","endTime":"0","summary":"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's \"Value\" category. Stocks with \"A\" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.One stock to keep an eye on is Takeda Pharmaceutical Co. . TAK is currently sporting a Zacks Rank of #2 , as well as a Value grade of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/value-investors-buy-takeda-pharmaceutical-144019451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4211","TAK","ISBC"],"gpt_icon":0},{"id":"2516399566","title":"Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2516399566","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516399566?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010438,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) and Takeda (TAK) said Monday that a phase 3 study of investigational drug rusfertide as a potential add-on to standard of care treatment for polycythemia vera, a form o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX","BK4139","BK4007","TAK"],"gpt_icon":0},{"id":"2516784687","title":"Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2516784687","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516784687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:45","pubTimestamp":1741002300,"startTime":"0","endTime":"0","summary":"Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo. All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes. Rusfertide was generally well tolerated; no new safety findings were observed in the study. \"The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class erythrocytosis-specific agent to address unmet medical needs in patients with PV who are unable to achieve adequate hematocrit control despite standard of care treatments,\" said Arturo Molina, M.D., M.S., Chief Medical Officer of Protagonist. \"We plan to submit additional details of these promising results for presentation at upcoming medical conferences in 2025. We are immensely grateful to the patients, study staff and principal inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protagonist-takeda-announce-positive-topline-114500048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","IE0002141913.USD","LU1674673691.USD","LU1244550494.USD","LU1074936037.SGD","IE00BVYPNV92.GBP","LU0345769631.USD","LU0795875169.SGD","LU1506573853.SGD","IE00BVYPNW00.USD","LU0882574055.USD","LU0122379950.USD","LU0466842654.USD","LU2592432038.USD","LU0320765646.SGD","LU1585245621.USD","LU0289739699.SGD","LU1059921491.USD","IE000M9KFDE8.USD","TAK","LU1066051811.HKD","LU2505996681.GBP","LU1894683348.USD","PTGX","BK4139","LU0640476718.USD","IE00B19Z3581.USD","LU0792757196.USD","LU1032955483.USD","IE00BJJMRZ35.SGD","LU1718418525.SGD","LU1929549753.HKD","LU0889566641.SGD","LU1244550577.SGD","LU1778281490.HKD","IE0034235303.USD","LU1935042991.SGD","LU0058720904.USD","LU1061106388.HKD","LU2602419157.SGD","BK4581","LU1894683264.USD","IE00BDGV0183.EUR","LU0203347892.USD","IE00BGHQF631.EUR","LU0234572021.USD","LU0345770308.USD","LU2129689514.USD","JNJ"],"gpt_icon":0},{"id":"2514313647","title":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313647","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313647?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the pivotal Phase 3SELECT-GCA trial that evaluated the efficacy and safety ofupadacitinib in adults with giant cell arteritis 1. The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, were met1. GCAis an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2. NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the approval of upadacitinib for the treatment of adult patients with GCA. The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA.*Sustained remission is defined as having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0661504455.SGD","LU2468319806.SGD","BK4599","CHMP","LU0882574055.USD","BK4139","BK4566","LU0198837287.USD","LU0689472784.USD","LU2347655156.SGD","LU0417517546.SGD","LU0943347566.SGD","BK4197","ABBV","LU1061106388.HKD","LU1934455863.HKD","LU0545039389.USD","LU1585245621.USD","LU0795875086.SGD","LU1718418525.SGD","LU0122379950.USD","SG9999003800.SGD","LU0114720955.EUR","LU0708994859.HKD","CPK","LU0861579265.USD","TAK","LU2237443978.SGD","BK4581","ALT","BK4534","LU1267930573.SGD","SG9999001440.SGD","LU0553294199.USD","LU1989771016.USD","LU1878469433.USD","LU2237443382.USD","LU0256863902.USD","LU0949170772.SGD","BK4007","LU1244550221.USD","RA","LU1037948541.HKD","LU1551013342.USD","LU1003077747.HKD","LU2237443895.HKD","LU0820561818.USD","IE00BJJMRZ35.SGD","BK4588"],"gpt_icon":0},{"id":"2514072568","title":"Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514072568","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514072568?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:43","pubTimestamp":1740663800,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now.In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited  stands against the other pharma stocks.The Rising Demand for Weight-Loss Medications and GLP-1 Developments. Competition with the leading companies in the anti-obesity business, which is expected to grow to $130 billion by 2030, is no longer the main emphasis. The possibility for additional participants to enter the field is growing along with the possible applications of GLP-1s. For example, the Swiss business Roche entered the weight-loss drug sweepstakes last year when it paid up to $3.1 billion to acquire California-based Carmot Therapeutics. The corporation wants to \"fast-track\" its anti-obesity medicines to regain faith in its pipeline and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-134320152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXQ63.HKD","BK4609","BK4007","BK4585","TAK","CAGR","IE00BMPRXN33.USD","IE00BMPRXR70.SGD","BK4159","BK4141","BK4588","BK4543","LU0348723411.USD"],"gpt_icon":1},{"id":"2513749337","title":"Takeda announces EMA approval for Takhzyro two mL pre-filled pen option","url":"https://stock-news.laohu8.com/highlight/detail?id=2513749337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513749337?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:17","pubTimestamp":1740392278,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolesc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-announces-ema-approval-for-takhzyro-two-ml-pre-filled-pen-option?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-announces-ema-approval-for-takhzyro-two-ml-pre-filled-pen-option?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2513748308","title":"Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2513748308","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513748308?lang=en_us&edition=fundamental","pubTime":"2025-02-24 17:26","pubTimestamp":1740389214,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co  said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab.The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said.Hereditary angioedema is a rare genetic disease that causes severe swelling in the body.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2513711489","title":"The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513711489","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513711489?lang=en_us&edition=fundamental","pubTime":"2025-02-24 16:01","pubTimestamp":1740384060,"startTime":"0","endTime":"0","summary":"TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent  and Adult Patients with HAE.1. The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1. ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda   announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO  for subcutaneous administration in adolescents  and adult patients with Hereditary Angioedema .1. The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life.\"HAE affects an estimated 1 in 50,000 people worldwide","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0012050646.USD","LU0205193047.USD","LU0205194284.USD","TAK","BK4007","LU1169590202.USD","IE00BLDYK493.USD","BK4198","LU0106261612.USD","IE00B64QTZ34.USD","HAE","LU1169589451.USD","MDCO"],"gpt_icon":0},{"id":"2512922084","title":"TAK vs. DSNKY: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512922084","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512922084?lang=en_us&edition=fundamental","pubTime":"2025-02-18 00:40","pubTimestamp":1739810413,"startTime":"0","endTime":"0","summary":"Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co.  and Daiichi Sankyo Co., Ltd. - Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Takeda Pharmaceutical Co. and Daiichi Sankyo Co., Ltd. - Sponsored ADR are sporting Zacks Ranks of #2  and #3 , respectively, right now. Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tak-vs-dsnky-stock-better-164013572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","TAK","DSNKY","BK4007"],"gpt_icon":0},{"id":"2511609700","title":"Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511609700","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511609700?lang=en_us&edition=fundamental","pubTime":"2025-02-16 03:43","pubTimestamp":1739648612,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025.In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited  stands against the other Japanese stocks.The current environment around Japanese markets is one of concern and relief, especially after U.S. President Donald Trump announced tariffs on steel and aluminum imports. Trump's threats to impose retaliatory tariffs on \"everyone\" have served as a harsh reminder of the dangers that all of America's trading partners, including Japan, face. With Trump aiming to reduce his country's trade imbalance with Japan, Japanese Prime Minister Shigeru Ishiba pledged to purchase more American LNG and disclosed plans for manufacturers such as Toyota and Isuzu Motors to invest more in the United States at their summit meeting on February 7. Homin Lee, senior macro strategist at Lombard Odier in Sing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-194332882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2511646325","title":"Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511646325","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511646325?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:40","pubTimestamp":1739544015,"startTime":"0","endTime":"0","summary":"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.Finally, we should also recognize that TAK has a P/CF ratio of 6.75. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 8.87. Over the past 52 weeks, TAK's P/CF has been as high as 7.10 and as low as 5.68, with a median of 6.35.USANA Health Sciences also has a P/B ratio of 1.09 compared to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-undervaluing-takeda-pharmaceutical-co-144015484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4532","BK4007","USNA","BK4183","ISBC","TAK"],"gpt_icon":0},{"id":"2509171776","title":"ADMA Loses 8.9% in a Month: How Should You Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509171776","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509171776?lang=en_us&edition=fundamental","pubTime":"2025-02-08 02:41","pubTimestamp":1738953660,"startTime":"0","endTime":"0","summary":"ADMA Biologics’ ADMA shares have lost 8.9% in a month against the industry’s growth of 6.6%.The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range . Total cash holdings at the end of 2024 grew to more than $100 million.The company’s top line currently comprises sales of three FDA-approved products — Bivigam , Asceniv  and Nabi-HB .Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.All pediatric patients in Asceniv’s post-marketing pediatric study have now completed their treatment schedule. ADMA expects to file its supplemental biologics license applicat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-loses-8-9-month-184100462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4139","BK4007","TAK","GRFS"],"gpt_icon":0},{"id":"2507645266","title":"Takeda Pharmaceutical Names Julie Kim Chief Executive","url":"https://stock-news.laohu8.com/highlight/detail?id=2507645266","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507645266?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:37","pubTimestamp":1738233435,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical (TAK) said Thursday it has appointed Julie Kim as chief executive.Kim, who is the president of the company's US business unit, will succeed Christophe Weber when he retires in June 2026.After retirement, Weber will not hold a seat on the board, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TAK","BK4191","BK4539","BK4007","WEBR"],"gpt_icon":0},{"id":"2507463306","title":"Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2507463306","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507463306?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:30","pubTimestamp":1738233045,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Busines...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-ceo-christophe-weber-to-retire-in-2026-julie-kim-to-succeed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-ceo-christophe-weber-to-retire-in-2026-julie-kim-to-succeed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","TAK","BK4007","BK4191","WEBR"],"gpt_icon":0},{"id":"2507643978","title":"Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2507643978","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507643978?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:03","pubTimestamp":1738231380,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical  reported fiscal Q3 core earnings Thursday of 132 Japanese yen  per basic share, down from 150 yen a year earlier.Four analysts polled by FactSet expected 124 yen.Revenue for the quarter ended Dec. 31 was 1.144 trillion yen, up from 1.111 trillion yen a year earlier.Analysts surveyed by FactSet expected 1.138 trillion yen.The company now expects core earnings guidance for the fiscal year ended March 31 to be 507 yen per share, compared with its prior guidance of 456 yen set on Oct. 31, 2024.Analysts surveyed by FactSet expect 480 yen.The company now expects revenue for the fiscal year of 4.59 trillion yen, compared with its prior guidance of 4.48 trillion yen. A single analyst polled by FactSet expects 4.562 trillion yen.Shares of the company rose 3.5% in premarket activity Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TAK"],"gpt_icon":0},{"id":"2507611283","title":"Takeda FY2024 Guidance Raised: Core Revenue And Profit Now Expected To Grow Low Single Digits; Core EPS Revised To Flat/Slight Decline. Free Cash Flow Raised To ¥550B–¥650B.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611283","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611283?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:26","pubTimestamp":1738221977,"startTime":"0","endTime":"0","summary":"FY2024 OutlookUpdating Full Year Management Guidance and Reported and Core ForecastsTakeda has upgraded its FY2024 Management Guidance, primarily driven by product momentum and OPEX savings. In addition, and also","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43328081/takeda-fy2024-guidance-raised-core-revenue-and-profit-now-expected-to-grow-low-single-digits-core-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0},{"id":"2507611990","title":"Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611990","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611990?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:04","pubTimestamp":1738220640,"startTime":"0","endTime":"0","summary":"CEO Christophe Weber to retire from Takeda in June 2026 after 12 years. Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process. Commenting on the selection process, Mr. Iijima said that \"after undergoing a multi-year succession process, the Board determined that Julie Kim is the best leader among a strong pool of both internal and external candidates. The selection process followed by the Nomination Committee and the Board has been thorough and exemplary.\". \"Takeda is a unique company, and I am deeply honored to have been chosen to lead it,\" said Julie Kim. \"Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase, together with our exceptional and talented people, while staying true to our strong culture that is rooted in o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/julie-kim-succeed-christophe-weber-070400823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEO","BK4007","WEBR","TAK","BK4191","BK4539"],"gpt_icon":0},{"id":"2507619884","title":"Takeda Pharmaceutical Q3 2024 GAAP EPS ¥15.01 Down From ¥67.38 YoY, Sales ¥1.144T Beat ¥1.139T Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2507619884","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507619884?lang=en_us&edition=fundamental","pubTime":"2025-01-30 14:49","pubTimestamp":1738219760,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43327774/takeda-pharmaceutical-q3-2024-gaap-eps-15-01-down-from-67-38-yoy-sales-1-144t-beat-1-139t-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Takeda Pharmaceutical Q3 2024 GAAP EPS ¥15.01 Down From ¥67.38 YoY, Sales ¥1.144T Beat ¥1.139T Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TAK\",params:#limit:5,,,undefined,":[{"date":"2025-07-30","symbol":"TAK","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.47,"defaultRemindTime":1753862400000,"name":null,"time":"","dateTimestamp":1753848000000,"actualEps":null},{"market":"US","date":"2025-01-30","symbol":"TAK","fiscalQuarterEnding":"2024/12","expectedEps":0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738213200000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2024-10-31","symbol":"TAK","fiscalQuarterEnding":"2024/09","expectedEps":0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730347200000,"reportTimeType":"pre","actualEps":0.44},{"market":"US","date":"2024-07-31","symbol":"TAK","fiscalQuarterEnding":"2024/06","expectedEps":0.37,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722398400000,"reportTimeType":"pre","actualEps":0.56},{"market":"US","date":"2024-05-09","symbol":"TAK","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":0}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TAK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TAK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1689307200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TAK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TAK","date":"2025-07-16","current":64.01121,"percent":0.9344,"low":9.919003,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"high":134.825067,"avg":34.297381,"sd":22.63937,"marketCap":46873253011.59},"quantilePoints":[{"date":"2020-07-17","current":130.667664,"twenty":28.683495,"median":36.800541,"eighty":86.385434,"marketCap":53972328180.49},{"date":"2020-07-24","current":133.164486,"twenty":28.804715,"median":36.81694,"eighty":87.725687,"marketCap":55658397179.21},{"date":"2020-07-31","current":49.030087,"twenty":28.880318,"median":36.830882,"eighty":88.33002,"marketCap":55557224542.23},{"date":"2020-08-07","current":49.695831,"twenty":29.000288,"median":36.883572,"eighty":88.247168,"marketCap":56220621340.2},{"date":"2020-08-14","current":51.954139,"twenty":29.120238,"median":36.973174,"eighty":88.149695,"marketCap":58424376584.77},{"date":"2020-08-21","current":52.698206,"twenty":29.210125,"median":37.019329,"eighty":87.725687,"marketCap":59589605364.98},{"date":"2020-08-28","current":51.875816,"twenty":29.296114,"median":37.194931,"eighty":87.39428,"marketCap":59006258563.45},{"date":"2020-09-04","current":50.217983,"twenty":29.358735,"median":37.349685,"eighty":86.853304,"marketCap":56544754820.4},{"date":"2020-09-11","current":51.079534,"twenty":29.413482,"median":37.496711,"eighty":86.502401,"marketCap":57600970548.14},{"date":"2020-09-18","current":52.071623,"twenty":29.482546,"median":37.644832,"eighty":86.409802,"marketCap":59718536367.45},{"date":"2020-09-25","current":51.23618,"twenty":29.528429,"median":37.70687,"eighty":86.307455,"marketCap":58079537631.11},{"date":"2020-10-02","current":47.267823,"twenty":29.55872,"median":37.818162,"eighty":86.127131,"marketCap":53733241411.92},{"date":"2020-10-09","current":48.45572,"twenty":29.570204,"median":38.056274,"eighty":85.695464,"marketCap":54928745380.19},{"date":"2020-10-16","current":45.740528,"twenty":29.581756,"median":38.101028,"eighty":85.328548,"marketCap":51955606617.4},{"date":"2020-10-23","current":45.688313,"twenty":29.610527,"median":38.151519,"eighty":85.068348,"marketCap":52213782354.12},{"date":"2020-10-30","current":90.341121,"twenty":29.668895,"median":38.172466,"eighty":85.328548,"marketCap":48419952386.27},{"date":"2020-11-06","current":96.588856,"twenty":29.692357,"median":38.217233,"eighty":86.409802,"marketCap":52398853598.67},{"date":"2020-11-13","current":100.410015,"twenty":29.692593,"median":38.315348,"eighty":87.847529,"marketCap":53780559103.29},{"date":"2020-11-20","current":101.776706,"twenty":29.697927,"median":38.413443,"eighty":88.520092,"marketCap":54951029488.93},{"date":"2020-11-27","current":104.091715,"twenty":29.726253,"median":38.431569,"eighty":89.212151,"marketCap":56090722051.49},{"date":"2020-12-04","current":108.749624,"twenty":29.809673,"median":41.476727,"eighty":89.840851,"marketCap":58500568009.94},{"date":"2020-12-11","current":107.940766,"twenty":29.825396,"median":42.195512,"eighty":90.113776,"marketCap":58227511975.44},{"date":"2020-12-18","current":108.136007,"twenty":29.898634,"median":42.406568,"eighty":90.568631,"marketCap":58641544051.05},{"date":"2020-12-24","current":104.063823,"twenty":29.940017,"median":42.671516,"eighty":90.966664,"marketCap":56275869966.77},{"date":"2020-12-31","current":104.733224,"twenty":29.971299,"median":42.851076,"eighty":91.332188,"marketCap":56879881356.69},{"date":"2021-01-08","current":103.059723,"twenty":29.97912,"median":42.920583,"eighty":91.791488,"marketCap":55589135003.46},{"date":"2021-01-15","current":100.437906,"twenty":29.989622,"median":43.181235,"eighty":92.111972,"marketCap":54236546808.57},{"date":"2021-01-22","current":100.047423,"twenty":30.031602,"median":43.418717,"eighty":92.258181,"marketCap":54029329143.49},{"date":"2021-01-29","current":103.143398,"twenty":30.073173,"median":43.598578,"eighty":92.394644,"marketCap":55216620705.7},{"date":"2021-02-05","current":31.781037,"twenty":30.157692,"median":43.665039,"eighty":92.535979,"marketCap":54432227223.55},{"date":"2021-02-12","current":31.919516,"twenty":30.223066,"median":43.441886,"eighty":92.526232,"marketCap":54935581599.54},{"date":"2021-02-19","current":31.997411,"twenty":30.238705,"median":43.337626,"eighty":92.438506,"marketCap":54757645997.71},{"date":"2021-02-26","current":31.00209,"twenty":30.269781,"median":42.961129,"eighty":92.297171,"marketCap":52506642547.95},{"date":"2021-03-05","current":32.525364,"twenty":30.307584,"median":42.874245,"eighty":92.272802,"marketCap":54273339139.55},{"date":"2021-03-12","current":34.741035,"twenty":30.314105,"median":42.671516,"eighty":92.258181,"marketCap":57572160306.5},{"date":"2021-03-19","current":36.991326,"twenty":30.320622,"median":42.376112,"eighty":92.258181,"marketCap":61377881020.81},{"date":"2021-03-26","current":36.385479,"twenty":30.34278,"median":42.069006,"eighty":92.219192,"marketCap":59972674222.12},{"date":"2021-04-01","current":35.38287,"twenty":30.371454,"median":41.476727,"eighty":92.150961,"marketCap":57783874962.89},{"date":"2021-04-09","current":32.481215,"twenty":30.393667,"median":38.431569,"eighty":92.111972,"marketCap":53478879478.89},{"date":"2021-04-16","current":32.082779,"twenty":30.470959,"median":38.377853,"eighty":92.111972,"marketCap":53250001858.4},{"date":"2021-04-23","current":31.900884,"twenty":30.513064,"median":38.294386,"eighty":92.058362,"marketCap":53341682665.94},{"date":"2021-04-30","current":31.485125,"twenty":30.533079,"median":38.21414,"eighty":91.833434,"marketCap":52029509066.16},{"date":"2021-05-07","current":31.831591,"twenty":30.534382,"median":38.169603,"eighty":91.791488,"marketCap":52970833572.63},{"date":"2021-05-14","current":15.564762,"twenty":30.470959,"median":38.145677,"eighty":91.758112,"marketCap":53496176267.97},{"date":"2021-05-21","current":15.876889,"twenty":30.319318,"median":38.091991,"eighty":91.609986,"marketCap":54795356598.76},{"date":"2021-05-28","current":15.664642,"twenty":30.236167,"median":38.041392,"eighty":91.546628,"marketCap":53587690959.61},{"date":"2021-06-04","current":15.281766,"twenty":30.057838,"median":37.818162,"eighty":91.527134,"marketCap":52499044333.6},{"date":"2021-06-11","current":15.732274,"twenty":29.940017,"median":37.70687,"eighty":91.283451,"marketCap":53886220157.49},{"date":"2021-06-18","current":15.499142,"twenty":29.705398,"median":37.644832,"eighty":91.259083,"marketCap":52855138856.99},{"date":"2021-06-25","current":15.64495,"twenty":29.653254,"median":37.496711,"eighty":91.185978,"marketCap":53110087882.29},{"date":"2021-07-02","current":15.624135,"twenty":29.556114,"median":37.309512,"eighty":90.966664,"marketCap":52790633079.89},{"date":"2021-07-09","current":15.170356,"twenty":29.369182,"median":37.239049,"eighty":90.713234,"marketCap":51765371608.86},{"date":"2021-07-16","current":15.553362,"twenty":29.036801,"median":37.034171,"eighty":90.649877,"marketCap":53089153550.44},{"date":"2021-07-23","current":15.445121,"twenty":28.610503,"median":36.990446,"eighty":90.630383,"marketCap":52540828243.5},{"date":"2021-07-30","current":13.400212,"twenty":26.987384,"median":36.968687,"eighty":90.397999,"marketCap":52641482781.37},{"date":"2021-08-06","current":13.231512,"twenty":25.788836,"median":36.881192,"eighty":90.295707,"marketCap":51739766156.6},{"date":"2021-08-13","current":13.399277,"twenty":25.542527,"median":36.851251,"eighty":90.284353,"marketCap":52624385513.69},{"date":"2021-08-20","current":13.340924,"twenty":25.375364,"median":36.822486,"eighty":90.167386,"marketCap":52391869685.63},{"date":"2021-08-27","current":13.304453,"twenty":25.07978,"median":36.81694,"eighty":90.040671,"marketCap":52184954198.97},{"date":"2021-09-03","current":13.585277,"twenty":24.895379,"median":36.800541,"eighty":89.938325,"marketCap":53414238064.1},{"date":"2021-09-10","current":13.6801,"twenty":24.732641,"median":36.787118,"eighty":89.91883,"marketCap":53684261064.92},{"date":"2021-09-17","current":13.906217,"twenty":24.583535,"median":36.72461,"eighty":89.874967,"marketCap":54565644835.19},{"date":"2021-09-24","current":13.753041,"twenty":24.444102,"median":36.66065,"eighty":89.831104,"marketCap":53563443001.25},{"date":"2021-10-01","current":13.260689,"twenty":24.187434,"median":36.617455,"eighty":89.777494,"marketCap":51482210756.95},{"date":"2021-10-08","current":11.666926,"twenty":23.93319,"median":36.601121,"eighty":89.748252,"marketCap":44862900501.13},{"date":"2021-10-15","current":11.787279,"twenty":23.7033,"median":36.578836,"eighty":89.499696,"marketCap":44516597060.99},{"date":"2021-10-22","current":11.681514,"twenty":23.539863,"median":36.5454,"eighty":88.968468,"marketCap":44293684279.19},{"date":"2021-10-29","current":10.648321,"twenty":23.423498,"median":36.488155,"eighty":88.710165,"marketCap":44164269191.12},{"date":"2021-11-05","current":10.784625,"twenty":23.226892,"median":36.468627,"eighty":88.627312,"marketCap":44983557825.66},{"date":"2021-11-12","current":10.950849,"twenty":22.951173,"median":36.398869,"eighty":88.490851,"marketCap":45493195113.2},{"date":"2021-11-19","current":10.728109,"twenty":22.593579,"median":36.365388,"eighty":88.33002,"marketCap":44596449686.83},{"date":"2021-11-26","current":10.425581,"twenty":22.055183,"median":36.25968,"eighty":88.252042,"marketCap":43512424769.26},{"date":"2021-12-03","current":10.106651,"twenty":21.515452,"median":36.172679,"eighty":88.178937,"marketCap":42286529642.36},{"date":"2021-12-10","current":10.142864,"twenty":21.321368,"median":36.088488,"eighty":87.847529,"marketCap":42348534488.31},{"date":"2021-12-17","current":10.34424,"twenty":21.015505,"median":36.02197,"eighty":87.423521,"marketCap":43082485607.36},{"date":"2021-12-23","current":10.363994,"twenty":20.795645,"median":35.82744,"eighty":87.174965,"marketCap":42874132957.12},{"date":"2021-12-31","current":10.327779,"twenty":20.657578,"median":35.632629,"eighty":86.517022,"marketCap":42437110052.52},{"date":"2022-01-07","current":10.522022,"twenty":20.640925,"median":35.562823,"eighty":86.434171,"marketCap":43033429977.32},{"date":"2022-01-14","current":11.009273,"twenty":20.536864,"median":35.556871,"eighty":86.322076,"marketCap":45750368973.66},{"date":"2022-01-21","current":10.940136,"twenty":20.171308,"median":35.520843,"eighty":86.263593,"marketCap":45488233052.08},{"date":"2022-01-28","current":10.953305,"twenty":19.949589,"median":35.455688,"eighty":85.922437,"marketCap":44994125510.56},{"date":"2022-02-04","current":12.019761,"twenty":19.86233,"median":35.393845,"eighty":85.355005,"marketCap":45736794370.02},{"date":"2022-02-11","current":12.502153,"twenty":19.831282,"median":35.308236,"eighty":85.302091,"marketCap":47298200126.65},{"date":"2022-02-18","current":12.558981,"twenty":19.671006,"median":35.308236,"eighty":85.302091,"marketCap":47834673171.52},{"date":"2022-02-25","current":12.196703,"twenty":19.550551,"median":35.308236,"eighty":85.302091,"marketCap":46263555485.74},{"date":"2022-03-04","current":12.289048,"twenty":19.380891,"median":35.308236,"eighty":85.302091,"marketCap":46976698663.99},{"date":"2022-03-11","current":12.043978,"twenty":19.117196,"median":35.308236,"eighty":85.302091,"marketCap":45095629553.81},{"date":"2022-03-18","current":12.707196,"twenty":18.980245,"median":35.308236,"eighty":85.302091,"marketCap":46769031069.82},{"date":"2022-03-25","current":12.770838,"twenty":18.858799,"median":35.308236,"eighty":85.302091,"marketCap":45895036970.15},{"date":"2022-04-01","current":12.530413,"twenty":18.69121,"median":35.308236,"eighty":85.302091,"marketCap":44742437445.66},{"date":"2022-04-08","current":13.064299,"twenty":18.623126,"median":35.308236,"eighty":85.302091,"marketCap":46073289723.14},{"date":"2022-04-14","current":13.294114,"twenty":18.443795,"median":35.308236,"eighty":85.302091,"marketCap":46294767383.12},{"date":"2022-04-22","current":13.21633,"twenty":18.221438,"median":35.308236,"eighty":85.302091,"marketCap":45025239824.55},{"date":"2022-04-29","current":13.325935,"twenty":17.979017,"median":35.308236,"eighty":85.302091,"marketCap":45022632781.95},{"date":"2022-05-06","current":13.53454,"twenty":17.700642,"median":35.308236,"eighty":85.302091,"marketCap":45566277364},{"date":"2022-05-13","current":24.629857,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":43848144051.53},{"date":"2022-05-20","current":25.018997,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":45016426783.75},{"date":"2022-05-27","current":25.119636,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":45470626890.48},{"date":"2022-06-03","current":24.280973,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":42728413394.89},{"date":"2022-06-10","current":24.368194,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":41777808638.38},{"date":"2022-06-17","current":23.83145,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":40560767412.66},{"date":"2022-06-24","current":24.871564,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":42352646298.73},{"date":"2022-07-01","current":25.220478,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":42911856821.29},{"date":"2022-07-08","current":26.059148,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":44046297256.04},{"date":"2022-07-15","current":26.763631,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":44459950529.79},{"date":"2022-07-22","current":26.817305,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":45321441244.41},{"date":"2022-07-29","current":30.743571,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":45477961048.28},{"date":"2022-08-05","current":29.247514,"twenty":15.868566,"median":35.251678,"eighty":85.31532,"marketCap":42639852719.36},{"date":"2022-08-12","current":29.748811,"twenty":15.868566,"median":35.071486,"eighty":85.31532,"marketCap":43951767417.68},{"date":"2022-08-19","current":29.8898,"twenty":15.868566,"median":34.741035,"eighty":85.31532,"marketCap":43038704613},{"date":"2022-08-26","current":29.874135,"twenty":15.868566,"median":33.797644,"eighty":85.31532,"marketCap":42969756201.7},{"date":"2022-09-02","current":30.022957,"twenty":15.868566,"median":32.525364,"eighty":85.31532,"marketCap":42304023842.38},{"date":"2022-09-09","current":30.65741,"twenty":15.868566,"median":32.307982,"eighty":85.31532,"marketCap":42457872052.31},{"date":"2022-09-16","current":30.406762,"twenty":15.868566,"median":32.13589,"eighty":85.31532,"marketCap":41975860478.2},{"date":"2022-09-23","current":29.784868,"twenty":15.868566,"median":32.082779,"eighty":85.31532,"marketCap":41053322910.74},{"date":"2022-09-30","current":29.611929,"twenty":15.868566,"median":31.991351,"eighty":85.31532,"marketCap":40398024705.55},{"date":"2022-10-07","current":29.784868,"twenty":15.868566,"median":31.910861,"eighty":85.31532,"marketCap":40490115913.28},{"date":"2022-10-14","current":30.091442,"twenty":15.868566,"median":31.822929,"eighty":85.31532,"marketCap":40007811364.69},{"date":"2022-10-21","current":29.234607,"twenty":15.868566,"median":31.680102,"eighty":85.31532,"marketCap":38943108088.84},{"date":"2022-10-28","current":27.96678,"twenty":15.868566,"median":31.562866,"eighty":85.31532,"marketCap":40412932074.34},{"date":"2022-11-04","current":27.990228,"twenty":15.868566,"median":31.51076,"eighty":85.31532,"marketCap":40544936411.09},{"date":"2022-11-11","current":28.209015,"twenty":15.868566,"median":31.374814,"eighty":85.31532,"marketCap":43206259311.05},{"date":"2022-11-18","current":28.704934,"twenty":15.868566,"median":31.254645,"eighty":85.31532,"marketCap":43730486647.27},{"date":"2022-11-25","current":29.426933,"twenty":15.868566,"median":31.201154,"eighty":85.31532,"marketCap":45057111010.77},{"date":"2022-12-02","current":28.931014,"twenty":15.868566,"median":31.037761,"eighty":85.31532,"marketCap":45570767384.44},{"date":"2022-12-09","current":29.835336,"twenty":15.868566,"median":30.937343,"eighty":85.31532,"marketCap":46637499358.3},{"date":"2022-12-16","current":30.331255,"twenty":15.868566,"median":30.871973,"eighty":85.31532,"marketCap":47313819017.43},{"date":"2022-12-23","current":29.900973,"twenty":15.868566,"median":30.772934,"eighty":85.31532,"marketCap":47996239753.01},{"date":"2022-12-30","current":29.981195,"twenty":15.868566,"median":30.71556,"eighty":85.31532,"marketCap":48463304453.77},{"date":"2023-01-06","current":29.755114,"twenty":15.868566,"median":30.572454,"eighty":85.31532,"marketCap":47870974965.36},{"date":"2023-01-13","current":29.864508,"twenty":15.868566,"median":30.484406,"eighty":85.31532,"marketCap":49882681588.13},{"date":"2023-01-20","current":30.426063,"twenty":15.868566,"median":30.426063,"eighty":85.31532,"marketCap":49943652563.58},{"date":"2023-01-27","current":30.148932,"twenty":15.868566,"median":30.406762,"eighty":85.31532,"marketCap":49467797966.47},{"date":"2023-02-03","current":23.618692,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":49524315647.28},{"date":"2023-02-10","current":23.884908,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":49885153889.85},{"date":"2023-02-17","current":23.681054,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":48373362782.36},{"date":"2023-02-24","current":23.799969,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":47942402215.74},{"date":"2023-03-03","current":24.043461,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":48450666632.88},{"date":"2023-03-10","current":24.621048,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50074775527.78},{"date":"2023-03-17","current":24.802252,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":51520828536.51},{"date":"2023-03-24","current":24.139732,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50698940566.02},{"date":"2023-03-31","current":24.63238,"twenty":15.872727,"median":30.373407,"eighty":85.302091,"marketCap":50868882296.85},{"date":"2023-04-06","current":24.898523,"twenty":15.872727,"median":30.373407,"eighty":85.302091,"marketCap":51908951328.51},{"date":"2023-04-14","current":25.289243,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52430478946.56},{"date":"2023-04-21","current":25.436471,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52090554629.18},{"date":"2023-04-28","current":25.549723,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52360758781.69},{"date":"2023-05-05","current":25.934781,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":53114594501.1},{"date":"2023-05-12","current":21.816188,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":51463307525.88},{"date":"2023-05-19","current":21.919152,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50148262100.11},{"date":"2023-05-26","current":22.174322,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50264110513.18},{"date":"2023-06-02","current":21.909524,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50016322403.86},{"date":"2023-06-09","current":22.247876,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50740318667.02},{"date":"2023-06-16","current":22.419504,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50575421543.16},{"date":"2023-06-23","current":22.547244,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":50034367985.85},{"date":"2023-06-30","current":22.199081,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48652831553.96},{"date":"2023-07-07","current":21.625347,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":47542321682.04},{"date":"2023-07-14","current":21.105555,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48436114801.39},{"date":"2023-07-21","current":21.512562,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48597606707.51},{"date":"2023-07-28","current":22.302484,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":47655983749.28},{"date":"2023-08-04","current":22.405905,"twenty":15.864404,"median":30.349157,"eighty":85.328548,"marketCap":47472091400.73},{"date":"2023-08-11","current":22.962958,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":47925971293.26},{"date":"2023-08-18","current":22.653484,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":46744998549.67},{"date":"2023-08-25","current":22.947484,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":47472892956.93},{"date":"2023-09-01","current":23.262116,"twenty":15.864404,"median":30.265696,"eighty":85.328548,"marketCap":48142626644.03},{"date":"2023-09-08","current":23.262116,"twenty":15.864404,"median":30.265696,"eighty":85.328548,"marketCap":47619131084.19},{"date":"2023-09-15","current":25.06738,"twenty":15.864404,"median":30.239629,"eighty":85.328548,"marketCap":51339735089.9},{"date":"2023-09-22","current":24.298853,"twenty":15.864404,"median":30.152523,"eighty":85.328548,"marketCap":49671905160.78},{"date":"2023-09-29","current":23.9378,"twenty":15.864404,"median":30.101284,"eighty":85.328548,"marketCap":48306094881.06},{"date":"2023-10-06","current":23.12801,"twenty":15.864404,"median":30.064639,"eighty":85.328548,"marketCap":46912236069.61},{"date":"2023-10-13","current":23.4478,"twenty":15.864404,"median":30.064639,"eighty":85.328548,"marketCap":47185225879.19},{"date":"2023-10-20","current":22.447168,"twenty":15.864404,"median":30.035164,"eighty":85.328548,"marketCap":45133632614.81},{"date":"2023-10-27","current":33.018744,"twenty":15.848805,"median":30.061417,"eighty":85.468491,"marketCap":42045438777.36},{"date":"2023-11-03","current":33.977052,"twenty":15.848805,"median":30.109117,"eighty":85.468491,"marketCap":43262280273.82},{"date":"2023-11-10","current":34.001614,"twenty":15.848805,"median":30.156114,"eighty":85.468491,"marketCap":43146195810.29},{"date":"2023-11-17","current":34.509223,"twenty":15.848805,"median":30.265619,"eighty":85.468491,"marketCap":43924997173.45},{"date":"2023-11-24","current":34.411351,"twenty":15.848805,"median":30.338548,"eighty":85.468491,"marketCap":44071202551.42},{"date":"2023-12-01","current":34.149357,"twenty":15.848805,"median":30.406762,"eighty":85.468491,"marketCap":44271809028.5},{"date":"2023-12-08","current":33.224188,"twenty":15.856081,"median":30.46982,"eighty":85.355005,"marketCap":44164475676.92},{"date":"2023-12-15","current":32.708387,"twenty":15.856081,"median":30.676992,"eighty":85.355005,"marketCap":44261463171.18},{"date":"2023-12-22","current":32.732997,"twenty":15.856081,"median":31.207345,"eighty":85.355005,"marketCap":44132705649.12},{"date":"2023-12-29","current":33.191488,"twenty":15.848805,"median":31.270394,"eighty":85.468491,"marketCap":45078827041.22},{"date":"2024-01-05","current":35.107326,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46553386498.52},{"date":"2024-01-12","current":35.467569,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46529118760.4},{"date":"2024-01-19","current":35.574004,"twenty":15.834252,"median":31.485125,"eighty":85.695464,"marketCap":46054562134.98},{"date":"2024-01-26","current":35.287452,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":45813893702.51},{"date":"2024-02-02","current":37.669312,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":45919514328.61},{"date":"2024-02-09","current":37.493246,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":44733412617.38},{"date":"2024-02-16","current":38.84015,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46075141205.13},{"date":"2024-02-23","current":39.033823,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46211688108.13},{"date":"2024-03-01","current":38.637675,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45954550562.52},{"date":"2024-03-08","current":38.311953,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":46140815426.08},{"date":"2024-03-15","current":37.871788,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45561442683.96},{"date":"2024-03-22","current":38.796134,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45585981704.56},{"date":"2024-03-28","current":37.000261,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":43584427473.65},{"date":"2024-04-05","current":36.269795,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":42616375994.67},{"date":"2024-04-12","current":36.498683,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":42430179712.64},{"date":"2024-04-19","current":35.820825,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":41294416133.79},{"date":"2024-04-26","current":35.997119,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41249770241.05},{"date":"2024-05-03","current":36.314041,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":42076379836.26},{"date":"2024-05-10","current":36.349255,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41627594417.07},{"date":"2024-05-17","current":44.976968,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41733682877.63},{"date":"2024-05-24","current":45.020529,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41285104836.56},{"date":"2024-05-31","current":45.445251,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41644103120.04},{"date":"2024-06-07","current":46.087779,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":42404430023},{"date":"2024-06-14","current":45.107651,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41300590483.72},{"date":"2024-06-21","current":43.866156,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":39610552206.76},{"date":"2024-06-28","current":45.436656,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":40691773038.88},{"date":"2024-07-05","current":46.209907,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":41429859502.63},{"date":"2024-07-12","current":47.281654,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":43144411716.7},{"date":"2024-07-19","current":46.533596,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":42599959119.02},{"date":"2024-07-26","current":46.698609,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":43774096625.98},{"date":"2024-08-02","current":44.272889,"twenty":15.841528,"median":31.485125,"eighty":84.95809,"marketCap":45300242074.37},{"date":"2024-08-09","current":43.014896,"twenty":15.841528,"median":31.485125,"eighty":84.034079,"marketCap":44025677518.59},{"date":"2024-08-16","current":45.710595,"twenty":15.841528,"median":31.485125,"eighty":83.611233,"marketCap":46246726032.37},{"date":"2024-08-23","current":46.418876,"twenty":15.841528,"median":31.485125,"eighty":83.285679,"marketCap":48080793858.92},{"date":"2024-08-30","current":45.805737,"twenty":15.841528,"median":31.485125,"eighty":82.840382,"marketCap":47110126928.06},{"date":"2024-09-06","current":45.150312,"twenty":15.841528,"median":31.485125,"eighty":82.567216,"marketCap":47633333133.33},{"date":"2024-09-13","current":43.733749,"twenty":15.841528,"median":31.485125,"eighty":82.35018,"marketCap":46692187320.02},{"date":"2024-09-20","current":45.192598,"twenty":15.841528,"median":31.485125,"eighty":81.917164,"marketCap":46914983400.73},{"date":"2024-09-27","current":44.008604,"twenty":15.841528,"median":31.485125,"eighty":81.717782,"marketCap":46173769906.47},{"date":"2024-10-04","current":44.8226,"twenty":15.841528,"median":31.485125,"eighty":81.193902,"marketCap":45207064894.75},{"date":"2024-10-11","current":45.034027,"twenty":15.841528,"median":31.485125,"eighty":80.903118,"marketCap":45273197191.14},{"date":"2024-10-18","current":45.203169,"twenty":15.841528,"median":31.485125,"eighty":80.121066,"marketCap":45314702691.87},{"date":"2024-10-25","current":43.395465,"twenty":15.841528,"median":31.485125,"eighty":79.259288,"marketCap":42802477236.79},{"date":"2024-11-01","current":23.34074,"twenty":15.841528,"median":31.394177,"eighty":76.252009,"marketCap":44255337707.7},{"date":"2024-11-08","current":23.061963,"twenty":15.841528,"median":31.223737,"eighty":52.659045,"marketCap":43818726338.15},{"date":"2024-11-15","current":23.302476,"twenty":15.841528,"median":30.720073,"eighty":52.113395,"marketCap":43649113935.95},{"date":"2024-11-22","current":22.482544,"twenty":15.841528,"median":30.492581,"eighty":51.914978,"marketCap":42094765685.01},{"date":"2024-11-29","current":22.318557,"twenty":15.841528,"median":30.428162,"eighty":51.719171,"marketCap":43004121919.03},{"date":"2024-12-06","current":22.537206,"twenty":15.841528,"median":30.363743,"eighty":51.54686,"marketCap":43593417925.5},{"date":"2024-12-13","current":22.602801,"twenty":15.841528,"median":30.265696,"eighty":51.06387,"marketCap":42654808427.14},{"date":"2024-12-20","current":22.438814,"twenty":15.841528,"median":30.156169,"eighty":50.729692,"marketCap":41620825476.96},{"date":"2024-12-27","current":22.89251,"twenty":15.841528,"median":30.11976,"eighty":50.270198,"marketCap":42157933916.75},{"date":"2025-01-03","current":22.854246,"twenty":15.841528,"median":30.084614,"eighty":49.695831,"marketCap":42120101324.52},{"date":"2025-01-10","current":22.526274,"twenty":15.834252,"median":30.039538,"eighty":48.706353,"marketCap":41387819255.78},{"date":"2025-01-17","current":22.072578,"twenty":15.834252,"median":29.98139,"eighty":47.742982,"marketCap":40954868347.09},{"date":"2025-01-24","current":22.056179,"twenty":15.834252,"median":29.928964,"eighty":47.376261,"marketCap":41086375616.12},{"date":"2025-01-31","current":32.066996,"twenty":15.834252,"median":29.8898,"eighty":47.184847,"marketCap":43068627249.87},{"date":"2025-02-07","current":31.518451,"twenty":15.834252,"median":29.8898,"eighty":46.698609,"marketCap":43370831342.3},{"date":"2025-02-14","current":31.625402,"twenty":15.834252,"median":29.8898,"eighty":46.623803,"marketCap":43271885610.15},{"date":"2025-02-21","current":32.135858,"twenty":15.834252,"median":29.8898,"eighty":46.463276,"marketCap":44737299221.36},{"date":"2025-02-28","current":33.019632,"twenty":15.834252,"median":29.8898,"eighty":46.1861,"marketCap":45710719655.87},{"date":"2025-03-07","current":33.965435,"twenty":15.826975,"median":29.881968,"eighty":45.994515,"marketCap":47968574450.17},{"date":"2025-03-14","current":32.579894,"twenty":15.826975,"median":29.881968,"eighty":45.856479,"marketCap":45709305301.84},{"date":"2025-03-21","current":33.462021,"twenty":15.826975,"median":29.881968,"eighty":45.756962,"marketCap":46697220950.86},{"date":"2025-03-28","current":32.837181,"twenty":15.826975,"median":29.881968,"eighty":45.646342,"marketCap":45537525126.69},{"date":"2025-04-04","current":32.910692,"twenty":15.826975,"median":29.881968,"eighty":45.486482,"marketCap":46959977925.4},{"date":"2025-04-11","current":28.911716,"twenty":15.834252,"median":29.864508,"eighty":45.423604,"marketCap":41903036554.51},{"date":"2025-04-17","current":30.516053,"twenty":15.834252,"median":29.864508,"eighty":45.37687,"marketCap":44665727413.14},{"date":"2025-04-25","current":31.299454,"twenty":15.826975,"median":29.853656,"eighty":45.205165,"marketCap":45236702475.67},{"date":"2025-05-02","current":32.353752,"twenty":15.826975,"median":29.853656,"eighty":45.143969,"marketCap":46627023849.03},{"date":"2025-05-09","current":62.186826,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":46246122430},{"date":"2025-05-16","current":59.013194,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":43629573670.78},{"date":"2025-05-23","current":60.272181,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":45243750600.82},{"date":"2025-05-30","current":62.428377,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":46713186360.41},{"date":"2025-06-06","current":62.153426,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":46690667816.43},{"date":"2025-06-13","current":62.934861,"twenty":15.826975,"median":29.853656,"eighty":45.099269,"marketCap":47259274399.65},{"date":"2025-06-20","current":62.052124,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"marketCap":45950911927.98},{"date":"2025-06-27","current":63.18087,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"marketCap":47191840400.65},{"date":"2025-07-03","current":64.005724,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"marketCap":47693415916.83},{"date":"2025-07-11","current":64.055104,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"marketCap":47209686047.66},{"date":"2025-07-16","current":64.01121,"twenty":15.819699,"median":29.842804,"eighty":45.065741,"marketCap":46873253011.59}],"updateTime":1752809377625}}}